Is Karyopharm Therapeutics Stock a Good Investment?
Karyopharm Therapeutics Investment Advice | KPTI |
- Examine Karyopharm Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Karyopharm Therapeutics' leadership team and their track record. Good management can help Karyopharm Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Karyopharm Therapeutics' business and its evolving consumer preferences.
- Compare Karyopharm Therapeutics' performance and market position to its competitors. Analyze how Karyopharm Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Karyopharm Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Karyopharm Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Karyopharm Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Karyopharm Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Karyopharm Therapeutics Stock
Researching Karyopharm Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 48.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 13.95. Karyopharm Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 26th of February 2025.
To determine if Karyopharm Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Karyopharm Therapeutics' research are outlined below:
| Karyopharm Therapeutics generated a negative expected return over the last 90 days | |
| Karyopharm Therapeutics has high historical volatility and very poor performance | |
| Karyopharm Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (76.42 M) with profit before overhead, payroll, taxes, and interest of 139.23 M. | |
| Karyopharm Therapeutics currently holds about 170.85 M in cash with (127.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14. | |
| Karyopharm Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - PR Newswire |
Karyopharm Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Karyopharm Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Karyopharm Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Karyopharm Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Karyopharm Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.2688 | -0.24 | 0.0288 | 10 | ||
2024-02-29 | 2023-12-31 | -0.31 | -0.36 | -0.05 | 16 | ||
2023-08-02 | 2023-06-30 | -0.34 | -0.29 | 0.05 | 14 | ||
2014-08-07 | 2014-06-30 | -0.49 | -0.55 | -0.06 | 12 | ||
2023-05-04 | 2023-03-31 | -0.37 | -0.3 | 0.07 | 18 | ||
2023-02-15 | 2022-12-31 | -0.35 | -0.43 | -0.08 | 22 | ||
2016-08-04 | 2016-06-30 | -0.76 | -0.84 | -0.08 | 10 | ||
2020-05-05 | 2020-03-31 | -0.69 | -0.78 | -0.09 | 13 |
Karyopharm Therapeutics Target Price Consensus
Karyopharm target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Karyopharm Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Karyopharm Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKaryopharm Therapeutics Target Price Projection
Karyopharm Therapeutics' current and average target prices are 4.10 and 4.50, respectively. The current price of Karyopharm Therapeutics is the price at which Karyopharm Therapeutics is currently trading. On the other hand, Karyopharm Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Karyopharm Therapeutics Market Quote on 7th of April 2025
Target Price
Analyst Consensus On Karyopharm Therapeutics Target Price
Karyopharm Therapeutics Analyst Ratings
Karyopharm Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Karyopharm Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Karyopharm Therapeutics' financials, market performance, and future outlook by experienced professionals. Karyopharm Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Karyopharm Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Karyopharm Therapeutics' institutional investor refers to the entity that pools money to purchase Karyopharm Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cam Group Holding A/s | 2024-12-31 | 1.5 M | Ubs O'connor Llc | 2024-12-31 | 1.5 M | Geode Capital Management, Llc | 2024-12-31 | 1.4 M | Goldman Sachs Group Inc | 2024-12-31 | 1.3 M | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 1.3 M | Deutsche Bank Ag | 2024-12-31 | 1.3 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Kennedy Capital Management Inc | 2024-12-31 | 1.2 M | Millennium Management Llc | 2024-12-31 | 1.2 M | Vanguard Group Inc | 2024-12-31 | 7.7 M | Adage Capital Partners Gp Llc | 2024-12-31 | 6.3 M |
Karyopharm Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.49 M.Market Cap |
|
Karyopharm Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.49) | |
| Return On Capital Employed | (1.66) | (1.57) | |
| Return On Assets | (0.46) | (0.49) | |
| Return On Equity | 0.41 | 0.43 |
Determining Karyopharm Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Karyopharm Therapeutics is a good buy. For example, gross profit margin measures Karyopharm Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Karyopharm Therapeutics' profitability and make more informed investment decisions.
Evaluate Karyopharm Therapeutics' management efficiency
Karyopharm Therapeutics has return on total asset (ROA) of (0.3688) % which means that it has lost $0.3688 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9105) %, meaning that it created substantial loss on money invested by shareholders. Karyopharm Therapeutics' management efficiency ratios could be used to measure how well Karyopharm Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Karyopharm Therapeutics' current Return On Equity is estimated to increase to 0.43, while Return On Tangible Assets are projected to decrease to (0.49). As of now, Karyopharm Therapeutics' Total Assets are increasing as compared to previous years. The Karyopharm Therapeutics' current Total Current Assets is estimated to increase to about 212.5 M, while Non Current Assets Total are projected to decrease to under 7.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.53) | (1.45) | |
| Tangible Book Value Per Share | (1.53) | (1.45) | |
| Enterprise Value Over EBITDA | (32.98) | (34.63) | |
| Price Book Value Ratio | (6.64) | (6.31) | |
| Enterprise Value Multiple | (32.98) | (34.63) | |
| Price Fair Value | (6.64) | (6.31) | |
| Enterprise Value | 5.9 B | 4.4 B |
Understanding the operational decisions made by Karyopharm Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.586 |
Basic technical analysis of Karyopharm Stock
As of the 7th of April, Karyopharm Therapeutics secures the Standard Deviation of 6.78, risk adjusted performance of (0.22), and Mean Deviation of 5.04. Karyopharm Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.Karyopharm Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Karyopharm Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Karyopharm Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Karyopharm Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karyopharm Therapeutics' Outstanding Corporate Bonds
Karyopharm Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Karyopharm Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Karyopharm bonds can be classified according to their maturity, which is the date when Karyopharm Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Karyopharm Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Karyopharm Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | (4.11) | |||
| Mean Deviation | 5.04 | |||
| Coefficient Of Variation | (529.04) | |||
| Standard Deviation | 6.78 | |||
| Variance | 45.93 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.24) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (4.12) | |||
| Maximum Drawdown | 35.08 | |||
| Value At Risk | (12.14) | |||
| Potential Upside | 11.18 | |||
| Skewness | 0.6991 | |||
| Kurtosis | 1.17 |
| Risk Adjusted Performance | (0.22) | |||
| Market Risk Adjusted Performance | (4.11) | |||
| Mean Deviation | 5.04 | |||
| Coefficient Of Variation | (529.04) | |||
| Standard Deviation | 6.78 | |||
| Variance | 45.93 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.24) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (4.12) | |||
| Maximum Drawdown | 35.08 | |||
| Value At Risk | (12.14) | |||
| Potential Upside | 11.18 | |||
| Skewness | 0.6991 | |||
| Kurtosis | 1.17 |
Consider Karyopharm Therapeutics' intraday indicators
Karyopharm Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Karyopharm Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Karyopharm Therapeutics Corporate Filings
F4 | 6th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
F3 | 6th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Karyopharm Stock media impact
Far too much social signal, news, headlines, and media speculation about Karyopharm Therapeutics that are available to investors today. That information is available publicly through Karyopharm media outlets and privately through word of mouth or via Karyopharm internal channels. However, regardless of the origin, that massive amount of Karyopharm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Karyopharm Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Karyopharm Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Karyopharm Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Karyopharm Therapeutics alpha.
Karyopharm Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Karyopharm Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Karyopharm Therapeutics Corporate Management
| Reshma MD | Chief VP | Profile | |
| Kristin Abate | Chief VP | Profile | |
| James JD | Chief Officer | Profile | |
| Lisa DiPaolo | Executive Officer | Profile | |
| Sohanya MBA | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.95) | Revenue Per Share | Quarterly Revenue Growth (0.1) | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Karyopharm Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.